Myoinositol plus α‑lactalbumin supplementation, insulin resistance and birth outcomes in women with gestational diabetes mellitus: a randomized, controlled study

To verify whether myo-inositol plus α-lactalbumin may reduce insulin resistance and excessive fetal growth in women with gestational diabetes mellitus. In a 12-month period, 120 women with a diagnosis of gestational diabetes mellitus were consecutively enrolled with an allocation of 1:1 in each group and randomly treated with myo-inositol plus α-lactalbumin plus folic acid (treated group) or folic acid (control group) for 2 months. Primary outcome was the variation of insulin resistance through the study evaluated by HOMA-IR. Secondary outcome was the evaluation, through the study, of fetal growth by ultrasound measurements of abdominal circumference centiles and estimated fat thickness. Some clinical outcomes were also considered. After 2 months, in the treated group, a signifcant reduction in insulin resistance (HOMA values 3.1± 1.4 vs 6.1 ± 3.4, p= 0.0002) and fetal growth was shown (Abdominal circumference centiles 54.9± 23.5 vs 67.5 ± 22.6, P= 0.006). Among clinical outcomes, a signifcant decrease in the rate of women who needed insulin (6.7% vs 20.3%, p= 0.03) and of pre-term birth (0 vs 15.2%, p= 0.007) was evidenced. A combination of myo-inositol and α-lactalbumin may reduce insulin resistance and excessive fetal growth